Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders
CNTA Stock | USD 16.95 0.96 5.36% |
About 61% of Centessa Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Centessa Pharmaceuticals PLC suggests that many traders are alarmed. The current market sentiment, together with Centessa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Centessa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Centessa |
BOSTON LONDON, Feb. 09, 2024 -- Centessa Pharmaceuticals plc announced that data from an additional 52-weeks of continuous treatment from the third year of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia, will be presented during an oral presentation at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders in Frankfurt, Germany, today, February 9, 2024. The Company previously shared Part
Read at finance.yahoo.com
Centessa Pharmaceuticals Fundamental Analysis
We analyze Centessa Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Centessa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Centessa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
Centessa Pharmaceuticals is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Centessa Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Centessa Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Centessa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Centessa Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Centessa Pharmaceuticals Related Equities
ERAS | Erasca | 12.94 | ||||
MLYS | Mineralys Therapeutics, | 5.64 | ||||
DSGN | Design Therapeutics | 4.67 | ||||
STRO | Sutro Biopharma | 3.77 | ||||
TRDA | Entrada Therapeutics | 2.16 | ||||
HLVX | Hillevax | 1.55 | ||||
IRON | Disc Medicine | 1.21 | ||||
OPT | Opthea | 0.54 | ||||
CRNX | Crinetics Pharmaceuticals | 0.33 | ||||
GLUE | Monte Rosa | 1.35 | ||||
LRMR | Larimar Therapeutics | 2.05 | ||||
CGEM | Cullinan Oncology | 2.08 | ||||
IPSC | Century Therapeutics | 2.33 | ||||
NUVL | Nuvalent | 2.49 | ||||
GNFT | Genfit | 3.80 | ||||
TARS | Tarsus Pharmaceuticals | 3.87 | ||||
EWTX | Edgewise Therapeutics | 4.42 | ||||
CCCC | C4 Therapeutics | 5.49 | ||||
NAMSW | NewAmsterdam Pharma | 6.18 |
Complementary Tools for Centessa Stock analysis
When running Centessa Pharmaceuticals' price analysis, check to measure Centessa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Centessa Pharmaceuticals is operating at the current time. Most of Centessa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Centessa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Centessa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Centessa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
CEOs Directory Screen CEOs from public companies around the world | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |